Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Disease associations for rare immune genetic variants require statistical or rule-based support.

Created on 19 Oct 2026

Authors

Paul E Gray, Stuart G Tangye, Edwin P Kirk

Published in

Journal of human immunity. Volume 3. Issue 1. Jan 04, 2027. Epub Oct 19, 2026.

Abstract

Validating weak gene-disease associations requires statistical support from large case-control studies. In contrast, strong (e.g., monogenic) gene-disease associations may be established from relatively few affected individuals, when independent orthogonal evidence converges. Here, we examine four publications associating heterozygous variants in five genes-TNIP1, P2RY8, BLK, BANK1, and SH2B3-with autoimmune disease (predominantly systemic lupus erythematosus [SLE]). While we do not dispute the molecular findings of these studies, we do not accept the proposed disease associations, which lack case-control evidence and where high minor allele frequencies in non-disease populations, indicate that the genotypes are far too common to represent Mendelian disease alleles. Additionally, 8 of 18 alleles were searchable in UK Biobank, and none showed enrichment in SLE. Until further evidence emerges, caution is warranted in ascribing disease association to heterozygous genotypes in TNIP1, P2RY8, BLK, BANK1, and SH2B3, and linkage to patients in clinical pedigrees should not be taken as inferring a monoallelic inborn error of immunity.

PMID:
42895470
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement